Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.

M FishmanJanice P DutcherJ I ClarkA AlvaG P MiletelloB CurtiNeeraj AgarwalR HaukeK M MahoneyH MoonJ TreismanS S TykodiG DanielsM A MorseM K K WongH KaufmanN GregoryD F McDermott

Published in: Journal for immunotherapy of cancer (2019)

PROCLAIM, NCT01415167 was registered with ClinicalTrials.gov on August 11, 2011, and initiated for retrospective data collection until 2006, and prospective data collection ongoing since 2011.

Keyphrases

high dose
electronic health record
big data
low dose
stem cells
machine learning
squamous cell carcinoma
squamous cell
deep learning
newly diagnosed